Latest International Markets News

BCAL Diagnostics has embedded referral forms for its early cancer detection tests into clinical software used by 97% of Australian GPs, launched a telehealth platform, and opened a Sydney clinic, gearing up for a multi-cancer test launch in June 2026.

ALS Limited reported a 25.8% jump in underlying net profit after tax to AUD 381.2 million for FY26, driven by strong commodity testing demand and margin expansion. The company raised its dividend and advanced major hub lab projects while navigating a post-year-end cyber incident.

Vista Group International is set to roll out its Digital Enablement platform across 88 Cineworld cinemas in the UK during 2026, building on last year’s deployment at 25 Picturehouse sites.

Temple & Webster has delivered its most profitable April ever with EBITDA hitting around $2.5 million, setting the stage for a near doubling of earnings in FY27 despite weak consumer confidence.

Bioxyne has locked in a two-year, $50 million exclusive supply agreement with German pharmaceutical distributor ADREXpharma, granting exclusive rights to its Dr Watson® brand in Germany and reinforcing its foothold in Europe’s largest medicinal cannabis market.

Life360 surged to $143.1 million in Q1 2026 revenue, powered by 27% growth in paying subscribers and a 329% jump in advertising following the Nativo acquisition. The company raised its full-year guidance as it navigates temporary user growth headwinds.

Merino & Co. secures a significant AUD 1.1 million order from its China distribution partner, marking the first major commercial milestone under its exclusive China distribution agreement and signalling growing demand for its wool products.

Bioxyne expands its LATAM footprint by securing the first international medicinal cannabis flower supply agreement in Costa Rica, with initial shipments valued over $500,000 planned before June 2026.

BCAL Diagnostics appoints Anne-Louise Arnett as CEO effective June 2026, aiming to accelerate its commercial rollout and international market entry of early cancer detection tests.

CSL Limited’s interim CEO Gordon Naylor reveals a downgraded FY26 outlook amid slower growth and announces substantial impairments tied to CSL Vifor assets. Leadership changes and transformation efforts aim to restore momentum.

Block, Inc. reported a robust Q1 2026 with AI-powered productivity gains, strong Cash App and Square growth, and a $5 billion share buyback boost. Despite a GAAP net loss due to restructuring and legal costs, the fintech giant raised its full-year outlook, signaling confidence in its AI-led transformation.

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.